News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Evotec Completes Strategic Sale of Just Evotec Biologics Toulouse Biomanufacturing Site to Sandoz to Expand European Biosimilar Capacity
Monday, December 08, 2025Evotec has closed the sale of its Just Evotec Biologics Toulouse site and granted a license to its continuous biologics manufacturing technology to Sandoz strengthening European biosimilar development and manufacturing capacity
UK life sciences sector set to benefit from new zero-tariff US pharmaceuticals trade deal and increased investment in innovative medicines
Friday, December 05, 2025The UK government has agreed a zerotariff pharmaceuticals trade deal with the US and pledged higher investment in innovative medicines reinforcing Europes life sciences competitiveness and manufacturing base
Bristol Myers Squibb’s Breyanzi Receives U.S. FDA Approval as the First CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma
Friday, December 05, 2025Bristol Myers Squibb has received approval from the US Food and Drug Administration FDA for Breyanzi a CDdirected CAR T cell therapy The treatment is authorised for adults with relapsed or refractory marginal zone lymphoma MZL
Celltrion Announces U.S. FDA Approval of 300 mg Strength of OMLYCLO®, the First and Only Interchangeable Biosimilar to XOLAIR®
Wednesday, December 03, 2025Celltrion has received approval from the US Food and Drug Administration FDA for a new mg mL presentation of OMLYCLO omalizumabigec OMLYCLO is the first and only FDAapproved biosimilar that is considered interchangeable
Ionis Receives U.S. FDA Breakthrough Therapy Designation for Zilganersen for Alexander Disease
Wednesday, December 03, 2025Ionis Pharmaceuticals has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to zilganersen for the treatment of Alexander disease AxD AxD is a rare
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
Tuesday, December 02, 2025Regeneron Pharmaceuticals and Tessera Therapeutics have entered into a global collaboration to develop and commercialise TSRA Tesseras lead in vivo Gene Writing therapy for alpha antitrypsin deficiency
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route Gene Therapy for Friedreich’s Ataxia
Tuesday, December 02, 2025Solid Biosciences has received Rare Pediatric Disease designation from the US Food and Drug Administration FDA for SGT its investigational gene therapy for Friedreichs ataxia FA The therapy is designed to deliver the fulllength
